Exchange Traded Concepts LLC Sells 13,083 Shares of Danaher Corporation $DHR

Key Points

• Exchange Traded Concepts LLC has reduced its stake in Danaher Corporation by 57.8%, selling 13,083 shares in the second quarter.
• Danaher reported an Earnings Per Share (EPS) of $1.80 for the last quarter, surpassing analyst expectations by $0.16.
• The company announced a quarterly dividend of $0.32 per share, with a dividend yield of 0.7% and a payout ratio of 27.23%.

Exchange Traded Concepts LLC lessened its position in Danaher Corporation (NYSE:DHR - Free Report) by 57.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,562 shares of the conglomerate's stock after selling 13,083 shares during the period. Exchange Traded Concepts LLC's holdings in Danaher were worth $1,889,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. GHP Investment Advisors Inc. lifted its position in Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares during the period. Heck Capital Advisors LLC bought a new position in Danaher during the fourth quarter valued at approximately $27,000. Sierra Ocean LLC lifted its position in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after purchasing an additional 76 shares during the period. Smallwood Wealth Investment Management LLC bought a new position in Danaher during the first quarter valued at approximately $31,000. Finally, Dunhill Financial LLC lifted its position in Danaher by 68.4% during the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after purchasing an additional 67 shares during the period. Institutional investors own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of research analyst reports. Robert W. Baird increased their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research report on Friday, July 18th. Barclays reaffirmed an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Wells Fargo & Company reduced their target price on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. UBS Group reduced their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Finally, Guggenheim reaffirmed a "buy" rating and set a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $246.35.

Danaher Stock Performance

Shares of NYSE:DHR opened at $193.31 on Monday. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90. The stock has a market capitalization of $138.42 billion, a P/E ratio of 41.13, a PEG ratio of 2.70 and a beta of 0.75. The firm has a fifty day simple moving average of $200.17 and a two-hundred day simple moving average of $198.18. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same period last year, the company posted $1.72 EPS. The business's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio (DPR) is presently 27.23%.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 11.10% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.